What is the equity of Immunome this year?
Immunome has equity of 119.88 M USD this year.
In 2024, Immunome's equity was 119.88 M USD, a 620.01% increase from the 16.65 M USD equity in the previous year.
Immunome's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Immunome's equity is essential for assessing its financial health, stability, and value to shareholders.
Evaluating Immunome's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Immunome's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Fluctuations in Immunome’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Immunome has equity of 119.88 M USD this year.
The equity of Immunome has increased/decreased by 620.01% increased compared to the previous year.
A high equity is advantageous for investors of Immunome as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
A low equity can be a risk for investors of Immunome, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
An increase in equity of Immunome can strengthen the company's financial position and improve its ability to make investments in the future.
A reduction in equity of Immunome can affect the financial situation of the company and lead to a higher dependence on debt capital.
Some factors that can affect the equity of Immunome include profits, dividend payments, capital increases, and acquisitions.
The equity of Immunome is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
To change equity, Immunome can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
Over the past 12 months, Immunome paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunome is expected to pay a dividend of 0 USD.
The current dividend yield of Immunome is .
Immunome pays a quarterly dividend. This is distributed in the months of .
Immunome paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
Immunome is assigned to the 'Health' sector.
To receive the latest dividend of Immunome from 10/25/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/25/2024.
The last dividend was paid out on 10/25/2024.
In the year 2023, Immunome distributed 0 USD as dividends.
The dividends of Immunome are distributed in USD.
Our stock analysis for Immunome Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunome Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.